Monitor for any follow-up from the FDA, as regulatory compliance issues in biotech can escalate. While the immediate risk appears mitigated by the company's response, continued scrutiny could impact investor sentiment or future promotional strategies.
Price Chart
Executive Summary
ImmunityBio submitted a comprehensive response to an FDA warning letter regarding promotional materials for its drug ANKTIVA, confirming a cited television ad was never aired and removing a podcast under review. The company is implementing enhanced compliance measures, including executive training and external oversight.
Key Facts
- FDA issued a Warning Letter on March 13, 2026, concerning promotional materials for ANKTIVA.
- ImmunityBio confirmed the cited television advertisement was never broadcast or disseminated.
- The company removed the identified podcast from its website and requested removal from third-party platforms.
- Corrective actions include mandatory executive training, expanded Promotional Review Committee (PRC) protocols, and engagement of external regulatory counsel.
- The statements in question were made during a podcast by Founder Dr. Patrick Soon-Shiong and were described as aspirational and forward-looking.
Financial Impact
No direct financial impact disclosed. No fines, penalties, or material financial adjustments were mentioned.
Risk Factors
- Potential for further FDA action if compliance concerns are not fully resolved.
- Reputational risk from regulatory scrutiny, which could affect physician or patient confidence in the company or its product.
- Risk of future non-compliance if internal controls are not effectively strengthened.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-142932 |
| Document: d70606dex991.htm | 0001193125-26-142932 |
| Document: 0001193125-26-142932-index-headers.html | 0001193125-26-142932 |
| Document: 0001193125-26-142932-index.html | 0001193125-26-142932 |
| Document: 0001193125-26-142932.txt | 0001193125-26-142932 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $6.95 $7.87 | ▲ +13.24% | ▲ +14.48% | $10.28 (+47.99%) |
Jul 6, 2026 12w ago | Insider Cluster | $8.91 $7.17 | ▼ −19.53% | ▼ −18.96% | $10.28 (+15.43%) |
Jul 1, 2026 13w ago | Insider Cluster | $9.20 $6.83 | ▼ −25.76% | ▼ −23.58% | $10.28 (+11.79%) |
May 18, 2026 19w ago | 8-K | $7.76 $6.99 | ▼ −9.92% | ▼ −10.91% | $10.28 (+32.54%) |
Apr 9, 2026 25w ago | 8-K | $7.48 $8.38 | ▲ +12.03% | ▲ +4.46% | $10.28 (+37.50%) |
Apr 6, 2026 25w ago | 8-K | $7.08 $7.43 | ▲ +4.94% | ▼ −4.04% | $10.28 (+45.27%) |
Feb 28, 2026 30w ago | Institutional Cluster | $10.44 $6.66 | ▼ −36.21% | ▼ −28.27% | $10.28 (−1.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access